Editas Medicine (EDIT) Tops Q3 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Editas Medicine (EDIT) Tops Q3 EPS by 5c

Editas Medicine Announces Third Quarter 2016 Results and Update

November 7, 2016 4:01 PM EST

Further strengthened leadership team with appointments of Charles Albright, Ph.D., as Chief Scientific Officer, and Gerald Cox, M.D., Ph.D., as Chief Medical Officer

CAMBRIDGE, Mass., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today reported financial results for the third quarter ended September 30, 2016, and provided an update on recent accomplishments and upcoming events.

We made important progress in the third quarter of 2016 across all three of our key strategic objectives, said Katrine Bosley, President and Chief Executive Officer of Editas... More